This summer, the U.S.-based biotechnology company Mage Biologics Inc was formed. Up to USD 28 million will be jointly invested in the new company, in which an antibody technology has been in-licensed from Inven2, based on research carried out in Professor Jan Terje Andersen’s lab.
“Mage Bio is developing a tailored monoclonal antibody that will be administered non-invasively. This is a completely new and innovative approach to the treatment of a serious chronic disease that causes inflammation and ulcers on the inner lining of the large intestine. There is clearly a need for a new treatment option for this patient group, and it will mean a lot for the patients if Mage Bio succeeds,” says Jan Terje Andersen, head of "The Laboratory of Adaptive Immunity and Homeostasis", which is part of both the University of Oslo and Oslo University Hospital.
Mage Bio plans to manufacture clinical-grade material this year, with the aim to file a clinal trial application in 2024. The focus indication will be ulcerative colitis, a chronic inflammatory bowel disease that impacts millions of patients all over the world. The humanized monoclonal antibody is bioengineered for optimal potency and tissue penetration and will be orally administered.
Read the complete original news article from the home page of inven2:
Licensing validates Norwegian platform technology for the development of tailored monoclonal antibodies
Inven2 is a limited liability company owned by the University of Oslo and Oslo University Hospital, and was established to administer the commercial potential of inventions and work results of these two institutions and all the health trusts in the South-Eastern Norway Regional Health Authority.
News article from MedWatch (in Norwegian):
Spesialistfond oppretter biotek-selskap med norsk teknologi som hovedkandidat: – En fantastisk validering for oss